Teva Pharma (TEVA) Tops Q3 EPS by 9c

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.32, $0.09 better than the analyst estimate of $1.23. Revenue for the quarter came in at $5.06 billion versus the consensus estimate of $5.09 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
• Hyperscale Data launches $300M at-the-market stock offering